שולי רווח תפעולי: Opus Bio (IRD)

לוגו תאגידי של חברת Opus Genetics Inc (IRD)

The stability of Opus Genetics Inc (IRD) is based on the monopoly status of its orphan drugs for the retina. The quarterly operating margin visualizes this resilience, where -777.70 serves as the current parameter value. High physician confidence is ensured by unique gene therapy vectors. The company's innovative developments are aimed at restoring vision to patients with rare hereditary defects.

Opus Genetics, Inc. (IRD): רווחיות מכירות לפי רווח תפעולי מ-25.10.2024 עד 19.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Opus Genetics, Inc. (IRD)

- מחיר מניה וקונצנזוס הערכת שווי:
ניתוח ראשוני של החברה:Opus Genetics, Inc., IRD
פריט של המותג Opus Genetics

Operating margin measures the efficiency of the core business by expressing the ratio of operating profit to revenue before accounting for financial expenses and tax liabilities. For Opus Genetics Inc (IRD), a monopoly position in gene therapy and inelastic demand create a sustainable foundation for profitability, reflecting the operating margin's trajectory as a guarantor of stable cash flow and high fundamental asset value.